Will Olsen
Founder of Engage Bio
Menlo Park, California
Overview
Work Experience
Co-Founder & CEO
2021 - Current
Engage Bio is developing Tethosomes, the next generation of non-viral DNA medicines. Tethosomes are highly potent, non-immunogenic, redosable, and titratable. At Engage, we're focused on building genetic medicines that scale. www.engagebio.com
Venture Partner
2019
Vice President of Development Operations
2019 - 2021
Developing TERT mRNA therapy to extend telomeres and increase the human healthspan.
Rejuvenation Technologies is a biotechnology company that developed nucleoside-modified TERT mRNA to safely and rapidly extend telomeres.
Raised $15,200,000.00 from Lifespan Vision Ventures and THE CATALYTIC IMPACT FOUNDATION (CIF).
Co-founder and Chief Operating Officer
2015 - 2020
Diagnostic platform for early detection of liver disease. Acquired by diagnostic developer DiscernDx.
Developing a novel diagnostic platform for early detection and diagnosis of liver disease.
Senior Program Manager
2015 - 2015
Designed and managed early-phase clinical programs. Participated in business development, including bid defenses and acting as technical sales lead.
Program Manager
2013 - 2015
Research Associate
2012 - 2013
Mount Sinai Health System delivers integrated medical care, research, and medical education through its network.
Raised $41,900,000.00 from National Institutes of Health, Hearst Health Prize., Multiple Myeloma Research Foundation, Steven & Alexandra Cohen Foundation and LifeSci NYC.
Economic Analyst Intern
2010 - 2010
Space Works Enterprises, Inc. is an aerospace engineering concept design and systems analysis.